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Introduction
Immune-based therapies for lhe treatment of breast cancer are now being designed to cir cumvent specific biologic problems that have been identified in the native immune response to brcast cancer. Advances in hasic immunology over the past decade have changed the scope and application of breast cancer immunotherapy. Perhaps the most important advances are the un derstanding that human tumors are immunogenic and the identification of tumor-specific antigens. In fact, hundreds of immunogenic proteins have been i,dentified in patients with cancer using high throughput technologies such as serological iden tification of aTltigens by recombinant expression cloning (SEREX). More importantly, we have be gun to identify proteins that are immunogenic in cancer whose function may be a causal com ponent in the malignant transfonnation. Thus. immune-based therapies targeting these biologi cally relevant antigens may re;.ult in the eradica tion of tumor cell clone~ that drive the initiation of malignancy.
The roles of the immune and tumoT microen ,rironment" in breast cancer greatly influence our approach to the design of immunotherapies. Stim ulation of both cytotoxic T cell (CTL) and CD4 'helper' T cell immunity is critically important for an effective antitumor response. In addition, cells of the innate immune system such as nat ural ki lIer (NK) cells are like Iy to play an im portant role in a balanced antitumor response. Cytokines and chemokines can both inhibit and stimulate immune rcspon"es and tumor growth. Moreover, the identification of the dendritic cell (DC) and the understanding or its role in ini tiating immunity to cancer has not only led to novel therapies for the treatment of breast can cer, but has focused attention on the major role of the antigen-presenting cell (APC) in initia tion or dampening of the tumor-specific immune respon,>c. We now know thal the tumor microen vironment is dynamic. Molecular disseclion of the evolution of the immune response occurring against autologous tumors in patients with ad vanced stage melanoma has demonstrated that the immune system is quite functional even in pa tients with significant ex.isting tumor burden. In fact, stimulating immunity ill patients with mea surable disease may have heneficial effects in immune augmentation. Apoptosis or necrosis of tumor cells may be an efficient method of antigen presentation for initiation of immune responses, Likewise, the presence of antigen during the evo lution of the immune response may be instru mental in generating T cell clonal expansion and epitope spreading. highlighting the occurrence of natural antigen-processing and the generation of endogenous tumor-specific immunity.
Finally, immune-based therapies are being ap plied clinically in different ways, both for treat ment <lnd prevention. Vaccines tnrgeting tumor antigens are increa~ingly being viewed and stud ied as chemopreventive agents designed to pro tect against cancer relap~e or devdup,ne~lt. Estab lished disease is being t(catcd with immune-based therapies. such as adoptive immunotherapy or in fusion of T cells allogeneic to host Ulmar cells therapies, designed to maximize T cell precursor frequencies. Thus, investigations of the immune syslCm at both the bench and bedside have Jed to the development of rmionally based immunother apies ror the prevention and treatment of breast cancer. Therapeutic approaches are now targeted to specific alterations in the evolution of the breast cancer-specific immune response. Many of these proteins are present at much higher concentrations io tTlal ignant ceJh than in the nor mal cells with which they are associated [5J. Gene mnplificalion results in overexpression of normal cellular proteins in cancer and is an etiologic factor in the malignant transformation of many solid rumors. Overexpre~sed oncoprotcins are not mutated and are distinct hom their normal coun terparts only by virtue of thcir greater concen tration in cancer cdh. Intuitively. tllese proteins would not be considered potential tumor antigens as patients should be tolerant to self-proteins. The recent finding, that many tumor antigens are self proteins. ha~ resulted in a 'paradigm shift' [6] . Thc new pamdigm includes self-proteins as tumor antigens and tolerance induction as a possible mechanism of inunune escape.
Breast cancer
A multitude of self-tumor antigem are present in breast cancer including. CEA, M UC-I, a vari ety of glycoproteins, p53, and ivlAGE-3 to name a few. or interest is the identification of im- Knutson et al. munogenic proteins in breast cancer that are also important cell regulatory proteins. By targeting the immune system to proteins that either in~tiatc or propagate the malignant phenotype, immune based therapies have the potential to eradicate the malignant clone. An example of two delined tumor antigen." that are involved in the carcino genic pathway of breast cancer are the HER 2jneu onc1.lgenic protein and telomerase.
One of the most extensively described tumor antigens in breast cancer is the HER-2jneu onco genic protein. HER-2jneu is a member of the epidennal growth factor receptor family and j~ a growth factor receptor [7, 8] . HER-2jneu is a transmemhrane protein that consists of a cysteine rich extracellular domain dIal functions in ligand binding and a cytoplasm.ic domain with kinase activity. In human~, the HER-2jneu protcin is ex pressed during fetal development [9) . In adults, the protein is weakly detectable in tlle epithe lia] cells of many normal tissues by immuno Ilistochemical staining. The HER-2jneu gene is present in nonnal cells as a single copy [9] . Amplification of the gene andjor overexpression of the associated protein have been identified in many human cancers such as breast, ovarian, pr(l~tate, non-small cell lung cancer, and colon cancer and is associated with a poor prognosis. The HER-2jneu oncogenic protein is also a tu mor antigen. Patients with different tumor type~ that overexpress the HER-2jneu protein can have both antibody rIOJ and T cell immunity directed against HER-2jneu rIll Existent immunity to HER-2/neu in humans was initially described in patients with breast cancer [3] .
Telomerase The cellular immune response can not be elicited without effective APC processing and presentation of tumor proteins to T cells. DC are potent APC and are important in initiating a T cell response. DC usually exist in peripheral tis sue in an immature state awaiting encounter with antigen. Immature DC are proficient at antigen uptake and processing bUl have no capacily to activale T cell~. Following exposure to antigen, DC migrate to regional draining lymph nodes (DLN) and it is during migration that DC at taio the ability to present antigen, i.e. undergo maturation. Antigen-specific T lymphocytes are then stimulated by direct contact with the DC. Although not well described for breast cancer, most tumors fail to express MHC class n and are, therefore, not direct targets of CD4-'-T cells.
The tumor cells would be immunogenic by other means such as uptake of the tumor cell debris by APC and 'cross-priming' [31] . The uptake, pro cessing, and presem3tion of exogenously derived tumor antigens by DC, therefore, is important for activation of CD4-T ceUs. DC can acquire antigen by multiple means induding endocytosis of soluble protein and phagocytosis of tumor derived exosomes and apoptotic bodies (12, 33] . Recent investigations have demonstrated that DC are llssociated with breast cancer tissue. Studies by Bell and colleagues have revealed that the mat uration state of the DC differs with proximity to the breast cancer lesion [34] . Immature DC reside within the lltmors, while mature DC are locllted in peritwnoral areas. The intratumoral localization or immature DC suggests that apoptosis-inducing or tumor necrotizing agents may be effective in treating breast cancer as tills may result in the cross-presentation of rumor-specific antigen to CD4 I T cells. Indeed, Candido and colleagues have recently observed that the level of tumor cell apoptosis is positively correlated to the effec tiveness of DC-hased therapy of murine MT-901 hreast carcinomas [35] . was neces~ary for migration of both CD4+ and CTL to twnor sites [40] . Thus, a major influence of IFNy at the tumor site may be a~ a chemoat tractam.
N K cells are also targets of cytokines and che mokines as recently described in murine breast cancer models. It is well known that IL-12 can directly mediate rumor killing. Many mecnanisms have been described for the effects of IL-12 in cluding increasing the local production of IFNy and the inrubition of angiogenesis [411. lL-12 is also known to directly stimulate NK cells [25] . N K cells can also be activated by the chemokine CKf1-1l to kill breasl cancer cells r42). CK~-11 functions as a chemoattractant for many immune effector ceUs including T cells, B cells, DC, and NK cells . In a study by Braun and col leagues, CK~-ll was transfected and ex-pressed intratumorally in murine breast cancer. The re sultant tumor rejection involved both NK and T lymphocytes.
Recent studies have focused on the in vivo modulation of APC fUJJction by eytokines which can act at many different levels including APC differentiation L46j, lifespan [47] , migration [43] , and antigen presentation r48]. Several cytokines arc known to promote dendropoj esis, ind ud ing lL-12 and Flt3 ligand, both of which have been shown to mediate tumor regression in vivo [49,50J. While the administration of either TL 12 or Flt-3 ligand increases the total number of circulating DC, IL-12 promotes myeloid den dropoiesis exclusively, while At3 ligand promotes both myeloid aJ:ld lymphoid dendropoiesis [46] . In a study by Esche and colleagues, the addi tion of both IL-12 and Flt3 ligand synergized the expression of MHC class 11. suggesting that anri gen presentation may be enhanced with combina tion cytokine treatment. Increasing the numbers of DC in the draining lymph nodes can poten tiate immune responses. DC die rapidly upon migration to the DLN, limiting the time of anti gen exposure and the resulting inunune response. A newly discovered TNF-related cytokine, TNF related activation-induced cytokine (TRANCE), has been shown to enhance the lifespan of ex vivo manipulated DC 147j. By increasing the lifespan of antigen-presenting DC in the DLN, T cell re sponses to antigen were substamially increased [47J. Cytokines can down-regulate immune re sponses as well. As an example, lysosomal pro teases of tbe cathepsin family are involved in pro cessing of antigen in the context of MHC class II. IFNy modulates cathepsin activity in cens [51 Knutson er af. nisms including tolerance, ,ignorance. inducing T cdl dYSfunction, and T cell death.
Tumor-specific immunity developing in a pa tient with advanced stage cancer is well docu mented. Coulie and colleagues recently published a I5-year chronology of immunologic studies of a melanoma patient with multiple recurrences but with a favorable clinical evolution due to im munologic intervention, hath natural and pharma cological [52] . The r-1ndings provided key in vivo evidence that the generation of an immune re sponse can potentia]]y result in the breakthrough of unrecoglllLed variam tumor ceJJs. The patient initially presented with a primary melanoma that was surgically removed. Following three relapses, a cell line. MEL A by the patient, was established from a subcutaneou:-metastases and the patient underwent repeated vaccinations with the cell line and was disease-free for 4 year:-. Th.ls disease free interval was associated with strong antitumor CTL response. ClL clones isolated from periph eral blood revealed several antigens produced by MEL A cells could be recognized in association with several HLA alleles. Eventually the patient relapsed with a tumor that had lost a complete HLA haplotype (A28-B44-Cw7). However, the original antigens were still expressed on the tu mOf. All of the CTL dones that were isolated before the relapse were A28-and B44-restricted. The development of escape variants has yet to be descrihed in breast cancer, hut as antigen-specific immune-based therapies are clinically tested eval uations of both antigen and immunostimulatory molecules on relapsed disease should be per formed. Studies such as this one demonstrate that cancer patients can develop functional immune responses but that tumors can evade restricted immune responses.
Tolerance to self-tumor antigens is a major obstacle to overcome in the development of sjg nificant tumor-specific lmmunity. Tolerance can be mediated centrally and peripherally. Central tolerance occurs when antigens are expressed intralhymically resulting in deletion of the self reactive T cells during early T cell differentiation rS31 Central tolerance is thoughl to delete pri mard)' high-affinity T celh that recognize domi nant peptide cpitopes, while lower-affinity T cells and those recognizing subdOnllnant epitopes are allowed to escape into the periphery. Central tol erance leads to irreversible loss of autoantigen reactive T cells by inducing apoptosis, and it is only Ihose autoreactive T cells that escape thymic deletion that are of importance clinically. The T cells that avoid thymic dearam:e, however. arc often tolerant or ignorant of tissues expressing the target antigens. As tumor antigen-specific T celh can he found in patients with cancer, it is clear thai Ihe ability to recognize cancer antigens is within the realm of the T cell repel10ire and that central tolerance is not complete. PeripheraJ tol erance Occurs extrathymicaUy and is mediated by both deletionaJ and non-deletional mechanisms [54) . The T cells UIa! have been tole.l1zed by non-de1etional methods are Ihe focus of inunune bas~u antitumor therapies. A major non-deletional mechanism of peripheral tolerance is anergy in duction. Anergy induction of antigen-specific T cells occurs by multiple mechanisms. The best understood mechanism of T cell anergy i.nduction is TCR signaling in the absence of co-stimulation. Activation of T cello;, is thought to involve at least Iwo independent signals, one mediated through the TCR : MHC complex and another through any of a variety of co-stimulatory receptors on T cells including CD28. Tumor cells, including breast cancer, uo not typicaJly express receptors (e.g. CD80) to the~e co-stimulatory molecules and may be responsible for anergy induction. In fact, recent reports demonstrate that even APC in the periph eral blood of carly stage breast cancer pat.ients demonstrate decreased expression of CDXO and CD86 [55] . Anergic T cel1s when rechallenged willi peptide-pulsed APC fail to proliferate and have reduced cytokioe release. Indeed, lJansfec tion of CDSO into many rumors. including breast cancer, can restore immune recognition and cause growlh alTest [561
The recovery of anergic T cells and the reversal of tolerance is critical to successful development of immune-based strategies for the treatment of breasL cancer. Although it is generally presumed that self-reactive T cells <Ire low-aflin-ity by virtue oftolerizing processes. recent evidence by Ohlco and colleagues suggest that higher-affinity periph erally tolerized tumor-antigen-specilic T cells can be recovered following multiple rounds of in vitro stimulation. Studie~ demonstraled that gag specific T cells could be isolated from mice trans genically engineered to express the Friend murine leukemia virus protein, gag, within hepatocytes 157J. The gag-specific T cells, after several in vitro stimulations with repeated IL-2 administra tion, displayed CTL activity and ,"vere comparable in affinity to the gag-specific T cells isolated from the parenLal mouse. C57BL/6, in which gag is a foreign antigen. These findings suggest the potential for circumvention of tolenmce and the recovery of high-affinHy tumor-specific T cells using ex vivo techniques.
Cytokines present within the tumor microenvi romncnt can also promote T cc11 anergy. The im munoregulalory cytokine, IL-IO. has previously been shown 10 induce a state of profound non responsiveness to melanoma and alloreactive T eel Is [58.59] . lL-lO acts dif(:~ctly on T cells dUling activation through CD28 anti can be reversed with exogenou') n.. Tumors c.:an induce T <.:ell dysfunction and even death. The C095/CD95L (Fas/FasL) sys tem play~ an important role in limiting the im muoe response. CD95jCD95L interactiollS result in apoptosis of C09S-expressing cells mediated by cwsslinking of CD95 hy CD95L. Muschen and colleagues studied 40 breast malignancies for the expression ofC095L l65]. They observed that CD95L expression was positively correlated with the grade of malignancy, with stage IV disease showing the highest rate of expression. Tn addi tion, in histologic analysis, they found that T cells within dose proximity of tumor cells were pre dominantly apoptotic. The authors concluded that tumor cell-induced apoptosis of tumor-associated T cells .is a potential mechanism o/" inmlUnosup pression in hreast cancer. To test this hypothesis, the investigators, in a separate study, examined apoptosis of lurkat T <.:ells following exposure to breast cancer cell Jines [661. They observed that the ratc of apoptosis of lurkat T cells was pos1tively correlated with the levels of CD95L
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expressed on the tumor cell lines. Apoptoti<.: ef fects were also enhanced by the addition of TFNy suggesting a detrimental effect of this cytokine at the tumor site. Moreover, in cancer patients. depletion of CD4+ and CDS-T cells in the pe ripheral blood was significantly correlated with CD95 expres~i{)n, suggesting both systemic and local immunosuppression.
Another mechanism of tumor-associated T cell dysfunction is acquired impairment in the Signal ing ability of the T cells. For example, in one study 9 of 14 breast <.:ancer patients had impaired levels of one or more signaling molecules: zeta chain. ZAP-70, p56lck, and MAP kinase phos phatase I [67J. This generalized immunosuppres sion is, at )east partially, mediated by the accu mulation of immature myeloid cells, Gr-l + [68] . The TCR zeta-chain can be reduced in T <.:eJJs by direct contact with Gr-l+ myeloid cells 169].
More recently, Gabrilovich and colleagues found that Or-I I cells purified from tumor-bearing mice directly inhibited tumor-antigen-specific CD8 T cells and had no impact on tumor-antigen-specific C04-T ceJJs [70] . The effe<.:ts of Or-I-I <.:ells depended on direct contact of the T cells with the Gr-I+ cells and could be abolished by inclusion of APC maturation factors (e.g. GM-CSF). These results suggest that therapies designed to promote the differentiation of myeloid cells, and hence, re verse zeta chain defe<.:ts may improve the success of therapies targeting activation of tumor-specific T cells.
Immune-based strategies in minimal disease
Vaccine strategies for breast <.:ancer are currently being designed to overcome tolerance and gen erate lasting immunity. As more effective im munization techniques are developed, the clinical application of breast cancer vaccines is being fo cused on patients with minimal disease. Vaccines targeting breast cancer arc often administered in the presence of bUlky disease and have had 1imi ted therapeutic success. Extrapolating from applica tion of active immunization in infectious diseases.
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vaccines such as those targeting chicken pox or influenza are given in the absence of infection and have only limited efficacy if administered after exposure to the pathogen. The goal of vaccination against breasl cancer may be to elicit significant immwlologic memory capable of ra{>idly expand ing an antigen-specific T ceO population in the presence of low levels of antigen encOlUltered during cancer onset or earl y relapse. Indeed, vac cination against breast cancer will likely only be effedive when di~ease is either absent or below the limit of detection. The two primary reasons for vaccloating in the absence of bulky disease are (I) patients with existing disease are often inununosupprcssed, and (2) the response to re peated vaccinati on in the absence of di sease is limited and reaches a plateau level thal is in sufficienT to eradicate existing malignancy before death occurs.
However, vaccination in the presence of some lumor may be beneficial during geneI:ation of the immune response due to epitope spread ing, apoplOsis, and necrosis of tumor cells. Epi tope spreading is an amplification or the im mune response that resulls from extending im munity from one antigen to other secondary antigens also expressed by the tumor cells. Epi tope, or determinant spreading, is a phenomenon first described in autoimmune diseases including Theiler's murine encephalomyelitis virus-induced demyelinating disea~e. murine experimental au toimmune encephalitis, and diabetes in non-obese diabetic mice [71] . It L~ thought that initiating an immune response against a single antigen can elicit inflammation that leads to tissue dllmage. Vaccination strategies to successfully immu nize against breast cancer are varied. All tech niques focus on enhancing the immunogenicity of the tumor ce]] or of a particular breaSl cancer associated antigelJ. Vaccines that have been trans lated to the cJinic include intact tumor celh transfected witn co-stimulatory molecules to en hance immunogcnicity, glycoprotein-hased vac cines given directly after the adminislration of dmgs such as c)'loxan to alter the immune mi cTllcnvironmenl, and protein-based vaccines ad ministered with multiple adjuvants to create local inflammatory respomes to augment the function of APC [73] . Methods of immunization that di rectly address the inadequacies of the pre-existent immune response to hreast cancer are more likely to resull in successrul inununizalion. One area of vaccine development. focused on augmenting APC function. is the use of DC as vaccine adju vants.
Much attention has been focused on the acti vation of DC during vaccination since DC initiate and sustain T (,;ell-mediated immune responses.
Target antigens can be delivered directly to ex vivo cuI lured DC followed by sub~equent inj~c tion of the DC-based vaccine. DC can also be modulated in vivo by using adjuvants that tar The disadvantages of using DC loaded or pulsed with tumor-associated antigens include the uncer tainty regarding the longevity of antigen presenta tion. the HLA restriction by the patient haplotype. and the relatively low number of known MHC class L and in particular, MHC class II T helper related epitopes. Whole tumor cell preparati.ons such as twnor lysatcs, apoptotic tumor cells, or DC-tumor cell fusions depend on the availability of tumor cells. In addition. the cytokines used in vitro to expand DC may affect their phagocytic activity and ability to migrate to DLN [77). Given
the problem~ with ex vivo generat.ion of DC, a potential solution La the difficulties of DC culture would be to mobilize DC .in vivo. Langerhans cells (LC) are sk.in DC and are the roost effec tive APC present in the skin. The soluble factors present in the dermis that recruit and mature skin DC, LC are well known [7 XI. Similar to other APC, the LC role is to recognjze, intemalj;r.e, and process antigen encountered in the skin and to transport antigen to the DLN for T cell recogni tion. As LC move from the skin to the DLN they lose their ability to process antigen and express high levels of MHC and co-stimulatory molecules such as CD80 and CD86 [78] . The functional maturation of LC is affected by epidermal cy tokines, in particular GM-CSE IL-l~, and TNFex and by stimulation with antigen mediated, in part, by co-"tirnulatory molecules.
OM-CSF, adm.inistered intradermally, can act as a recruitment and maturation factor for LC [79, 801 . GM-CSF, as an adjuvant can mobilize skin DC in vivo and has been used in vac cines targeting patients with breast cancer. Our laboratory has been conducting phase I clini cal vaccine trials using peptide-based vaccines in breast and ovarian cancer patients with HER 2/neu-overexpressing rumors [741. The HER 2/neu peptide-based vaccines consisted of BLA class II binding peptides admixed with GM-CSf. Our initial clinical vaccination strategies have concentrated on eliciting a CD4+ T helper re sponse; vigorous T helper response may serve to augment the production of HER-2/nen antibodies and/or HER-2/neu-specific CTL both of which could be Iherapemk In addition, CD4+ T cells playa major role .in the maintenance of immuno logic mcmory. Patients were immunized once a month for 6 months. and 38 patients completed the planned six vaccinations [81]. The major ity of patients could he immunized to at least one of the peptides in their vaccine. indicative of immune competence of the selected popula tion. In addition. over half of the patients devel oped HER-2/neu protcin-specific immunity after peptide immunization. The HER-2jncu protein specific T cell responses were similar in magni tude to response~ generated to a foreign antigen, keyhole limpet hemocyanin. All interesting tind ing of this study was that greater than 75% of the patieots who completed the course of vaccina tions developed intramolecular epitope spreading to HER-2/neu peptidcs not contained within their vaccine preparation. Strikingly, epitope spread ing wa~ significantly associated with the devel opment of HER-2/neu protein-specific immunity, consistent with the notion that epitope spreading is a function of natural endogenous processing of antigen L8I J. In addition, immunity to HER-2/nen protein was durahle and lasted for at least I year following the end of the vaccinations. An addi tional arm of dIe study evaluated immunization of patients with helper epitopes th::lt encompassed within theh' natural sequence HLA-A2 binding motifs. The rationale for this approach is that CD4+ T cell help is required for the generation of CD8+ T cel) responses that are long-lived. We ex amined immune responses to both the helper and HLA-A2 peptides in HLA-A2 patients selected to receive this vaccine formulation. The majority of patients developed both HER-2/neu peptide and protein-specific T cell immunity. Peptide re sponses could be identi fied to hotll the Jonger class II cpitope~ as well a~ tile HLA-A2 binding peptides. The peptide-specific CD8+ T cells \vere able to lyse HLA-matched HER-2/neu expressing tumor cells, and significant precursor frequen<:ies persisted for greater than I year. These resuH~ demonstrate that durable T cell immunity can be generated in breast cancer patients and dlat vaccines can be developed that are capable of sti mulating natural processing and presentation of antigen in vivo.
Immune-based strategies in advanced disease
The role of breast cancer vaccines may be in preventing cancer relapse or even, eventually. the development of tumors. However, the use of can cer vaccines as a treatment modality in eradicating established malignancy is questionable. Extrapo lating ii'om infectiou~ disease modeb, T cell pre cursor frequencies after influenza immunization Olay range from I : 25,000 to 1: 5000. However, during an active infection. the antigen-specific T cell precursor frequency lUay achieve levels of 1 : 50 circulating T cells. Immune-ba:;cd strate gies in advanced stage breast cancer must focus on increasing the tumor-specific T cell precllIsor frequeucy to a therapeutic rather than protective level. Examples of therapeutic interventiom tbat may potentially be effective in eradicating exist ing breast <:ancer include antigen-specific adop tive T cell therapy and tlle generation of a mixed chimera in vivo stimulating a grnft vs. tumor effect via allotransplantation.
Thc primary purpose of adoptive T cell therapy is to augment T cell responses over and above that In marked contrast, Tc2 recipients had greatly re duced histologic GVRD. These data indicate that immunocompetent cclls allogeneic to the mam mary carcinoma cells were able to inhibit tumor development in the primary host an.d to prevent tumor growth in the adoptive recipieot, which suggests that allogeneic cell therapy may be an efficient antitumor therapy for breast cancer.
Although aUoHSCT has shown promise as a therapeutic strategy in advanced stage renal cell carcinoma [98] , whether the modality has rele vant clinical implication.'. in patients with breast cancer is still unknown but there is anecdotal clinical evidence to support this possibility [99 10 I] . Eibl and colleagues reported a 32-year-old woman with inflammatory breast C,illcer who re ceived an allogeneic hone marrow transplant from un HLA-identical sihling 199J. The myeloablative conditioning regimen consisted of cyclophospha In..ide, thiotepa. and carboplatin. Resolution of the patient's liver metastases was observed simultane ously with the development of clinical GYHD in the first weeks after transplant. CTL. derived from the patient, were tested in a chromium-rele:Jse assay against Band T lymphocytes of the pa tient and donor collected prior to transplant as we]] as against a panel of hreast cancer cell lines. The T cells recognized host ceJls but not HLA identical donor cells. Recognition was MHC class 1 antigen-restricted. In addition, minor histocom patibility antigen (MiHA)-speci fic ar1d MHC class I antigen-restricted cytotoxic T lymphocytes rec ognjzing breast cancer cells were isolated from the peripheral blood of the patient. Four of eight breast cancer lines were recognized by CTL; three of them shared the HLA antigens HLA-A2, B44, and DR!. Similarly. Ueno and colleagues treated 10 metastatic breast cancer patients with high dose chemotherapy (cyclophosphamide, BeN U, and thiotepa) and alloHSCT tlOOl All patients engrafteJ and had hematologit· recovery. Shortly after transplantation, one patient achieved a com plete remission, five achieved a partial remis sion, and four had stable disease. In two patients, metastatic liver lesions regressed with the onset of acute GHVD, suggesting a GVT effect.
These studies suggest a possible aVT effect in hreast cancer; however, the results are not definitive and there is signil1cant concern over subjecting patients to the potential risks associ ated with conventional allogeneic transplantation. These potential risks include GVHD and major orga.n dysfunction as a sel\uelae of myeloahlative preparative regimens. The demonstration that an immune-mediated GVT effect plays a central role in the therapeutic efficacy of alloHSCT has led to the development of less intense conditioning reg imens which arc adequately immunosuppressive to pemlit the engraftmellt of donor hematopoi etic stem cells. A variety or non-myeloablative conditioning regimem have been reported L102 Ion All regimens share tIle similar goal of pro viding sufficient immUIlosuppression to achieve allogeneic donor engraftmcm while attempting to minimize lOxicity. Rizzieri and colleagues at Duke Univer~ity have re<:cntly reported ini tial result') using non-myeloablalive alJoHSCT in tbe setling of metastatic breast cancer [108] . following a conditioning regimen of Carnpath IH, fludarabine, and cyclophosphamide, five pa tients with metastatic breast cancer underwent alloHSCT. At a median follow-up of 90 day~, three patients had bee)) observed to have a partial response after transplantation. At the time of this report, four of the five patiems had maintained a partial response or stable disease.
Several observations can he made from these early trials. The data indicate that engraftment of donor hematopoietic stem celh may OCCU( with both filldarabine-and radiation-based regimens.
However, as shown in other studies, there is great variability relative to the degree of donor engrafr ment, and graft rejection is a significant problem [102, J09] . Although these regimens have pro vided many of the anticipated advantages, many of the problems that have been associated with mycloablmive alloHSCT persist. e.g. aVHD, and will have to be addressed in future trials.
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Conclusions
Breast cau<:er is an immunogenic tumor. Patients develop immune responses against spccific pro teins regulating the growth of their tumors. but the immunity that occurs endogenously is not ef fective for tumor eradication. Both the immune microenvironment and the tumor microenviron ment influence the initiation and propagation of breast cancer-specific immunity. As the complex interplay between T cells, cytokines. APC, tu mor ceUs, and other immune effectors i,; unrav eled, immunotherapy targeting breast cancer can be more rationally designed. Clinically, the ap plication of immune-based treatment to breast cancer is dictated by stage of disease. Recent cli n.i cal studies are demonstrating the generation of immune responses after active immunization. Hopefully, advance~ defining immunity to breast cancer at the bench will result in 'iimilar successes in the application of the immunotherapies in the clinic. 
